...
首页> 外文期刊>Molecular Cancer >circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer
【24h】

circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer

机译:CircnFib1通过MiR-486-5P / PIK3R1 / VEGF-C轴抑制淋巴管发生和淋巴结转移,在胰腺癌中

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Patients with lymph node (LN)-positive pancreatic ductal adenocarcinoma (PDAC) have extremely poor survival rates. Circular RNAs (circRNAs), a newly discovered type of endogenous noncoding RNAs, have been proposed to mediate the progression of diverse types of tumors. However, the role and underlying regulatory mechanisms of circRNAs in the LN metastasis of PDAC remain unknown. Next-generation sequencing was used to identify differentially expressed circRNAs between PDAC and normal adjacent tissues. In vitro and in vivo experiments were conducted to evaluate the functional role of circNFIB1. RNA pulldown and luciferase assays were performed to examine the binding of circNFIB1 and miR-486-5p. In the present study, we identified that a novel circRNA (circNFIB1, hsa_circ_0086375) was downregulated in PDAC and negatively associated with LN metastasis in PDAC patients. Functionally, circNFIB1 knockdown promoted lymphangiogenesis and LN metastasis of PDAC both in vitro and in vivo. Mechanistically, circNFIB1 functioned as a sponge of miR-486-5p, and partially reversed the effect of miR-486-5p. Moreover, circNFIB1 attenuated the oncogenic effect of miR-486-5p and consequently upregulated PIK3R1 expression, which further downregulated VEGF-C expression through inhibition of the PI3K/Akt pathway, and ultimately suppressed lymphangiogenesis and LN metastasis in PDAC. Our findings provide novel insight into the underlying mechanism of circRNA-mediated LN metastasis of PDAC and suggest that circNFIB1 may serve as a potential therapeutic target for LN metastasis in PDAC.
机译:淋巴结(LN)淋巴结(LN)阳性胰腺导管腺癌(PDAC)的存活率极差。已经提出了圆形RNA(CircRNA),新发现的内源性非分量RNA,以介导各种类型的肿瘤的进展。然而,PDAC LN转移中Circrnas的作用和潜在的调节机制仍然是未知的。使用下一代测序来识别PDAC和正常相邻组织之间的差异表达的晶体。在体外和体内实验中进行了评估QiCnFib1的功能作用。进行RNA下拉和荧光素酶测定以检查CirnNFIB1和MIR-486-5P的结合。在本研究中,我们确定了一种新型CircrNA(CircnFib1,HSA_CIRC_0086375)在PDAC中下调,与PDAC患者的LN转移负相关。在功能上,Circnfib1在体外和体内敲低促进PDAC的淋巴管生成和LN转移。机械地,CircnFib1用作miR-486-5p的海绵,部分逆转MiR-486-5P的效果。此外,CirnNFIB1减弱了miR-486-5p的致癌作用,并因此通过抑制PI3K / akt途径进一步下调VEGF-C表达,并最终抑制了PDAC中的淋巴管发生和LN转移。我们的研究结果提供了对PDAC的Circrna介导的LN转移的潜在机制的洞察力,并表明CircnFib1可以作为PDAC中LN转移的潜在治疗靶标。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号